menu
    • menu
    [{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclacel Pharmaceuticals Inks Collaboration With University of Edinburgh to Study CDK Inhibitors in COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel\u2019s Clinical Stage CDK2\/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclacel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the at the EORTC-NCI-AACR Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Institute of Cancer Research's New Drug Targeting High-Risk Children\u2019s Cancer is Ready for Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"N-Myc","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Cyclacel","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Cyclacel"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ University of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ University of Texas"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Reports Preliminary Data From Its Phase 1\/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2\/CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fadraciclib

    Menu

    Fadraciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN...

                            Details : CYC065 (fadraciclib) is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. It is under phase 1/2 clinical development for the treatment of advanced solid tumor...

                            Brand Name : CYC065

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid...

                            Details : In a prior Phase 1 open-label trial CYC065 (fadraciclib), a CDK2/9 inhibitor, patients with high copy CCNE (cyclin E), MYC or MCL1 showed sensitivity to intravenously administered, single-agent fadraciclib.

                            Brand Name : CYC065

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2022

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Vene...

                            Details : Results from the study confirmed that CYCO65 (fadraciclib), inhibited CDK9 mediated transcription, reduced levels of the short-lived anti-apoptotic protein MCL1, and induced apoptosis in primary CLL cells.

                            Brand Name : CYC065

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2022

                            Lead Product(s) : Fadraciclib,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The Institute of Cancer Research

                            Country arrow
                            Discovery on Target
                            Not Confirmed

                            The Institute of Cancer Research

                            Country arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cyclacel Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The Institute of Cancer Research's New Drug Targeting High-Risk Children’s Cancer is Ready for Trials

                            Details : Scientists at The Institute of Cancer Research, London, have found an indirect way to target N-Myc, in a move that could be a game-changer for children with aggressive neuroblastoma.

                            Brand Name : CYC065

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 05, 2020

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cyclacel Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the at the EORTC-NCI-AACR Symposium ...

                            Details : Abstract highlighting clinical data with Cyclacel's CDK2/9 inhibitor fadraciclib has been selected for an oral presentation at the 32nd EORTC-NCI-AACR (ENA) Symposium 2020 being held virtually on October 24 – 25, 2020.

                            Brand Name : CYC065

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2020

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Cyclacel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in ...

                            Details : The publication, authored by scientists from Cyclacel and The Institute of Cancer Research, London, describes the discovery of fadraciclib and shows its ability to target CDK2 and CDK9, leading to broad therapeutic potential.

                            Brand Name : CYC065

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 13, 2020

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Edinburgh

                            Country arrow
                            Discovery on Target
                            Not Confirmed

                            University of Edinburgh

                            Country arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Cyclacel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cyclacel Pharmaceuticals Inks Collaboration With University of Edinburgh to Study CDK Inhibitors in COVID-19

                            Details : The parties will assess Cyclacel’s fadraciclib and seliciclib , its clinical stage CDK2/9 inhibitors, for their suitability for use in safety and efficacy studies in COVID-19 patients.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 20, 2020

                            Lead Product(s) : Fadraciclib

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Cyclacel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth